Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Tumor biomarkers tests use in diagnosis of cancer include, prostate specific antigen (PSA), circulating tumor cells (CTC), Alfa-fetoprotein test (AFP), CA-19 test for pancreatic cancer, HER-2 test, BRCA test, ALK test for lung cancer, carcioembryonic test (CEA), EGFR mutation test, and RAS mutation test.

The global cancer diagnostics market is estimated to account for US$ 45,106.5 Mn in terms of value and is expected to reach US$ 83,641.9 Mn by the end of 2027.

Global Cancer Diagnostics Market: Drivers

Increasing prevalence of cancer is expected to propel growth of the global cancer diagnostics market over the forecast period. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.

Moreover, R&D in cancer diagnostics is also expected to aid in growth of the market. For instance, in January 2020, researchers from Universidade do Porto, Portugal, reported assessment of the role of O-glycosylation using glycoengineered gastric cancer models in the detection of CD44v9 – a major protein splice variant isoforms expressed in human gastrointestinal cancer cells—by monoclonal antibodies. 

Biopsy held dominant position in the global cancer diagnostics market in 2019, accounting for 35.1% share in terms of value, followed by Imaging and Tumor Biomarkers Tests, respectively.

Figure 1. Global Cancer Diagnostics Market Share (%), by Value, by Test Type, 2019

Cancer Diagnostics  | Coherent Market Insights

Global Cancer Diagnostics Market: Restraints

Inadequate reimbursement policies are expected to hinder growth of the market. There have been various advancements in radiology with regard to imaging equipment in the recent past. However, most medical insurance companies do not offer reimbursement for procedures using Computer-aided Detection (CAD). As a result, people tend to choose conventional methods for diagnosis such as biopsy, pathological test or conventional imaging methods such as mammography, and MRI procedures.

Moreover, high price of cancer detection software is also expected to hamper growth of the market. Computer-aided Detection (CAD) software is available with a one-year license and hospitals have to renew it each year. Moreover, some insurance providers are opting out of the CAD procedure reimbursement as it is deemed extravagant and not preferred by senior radiologists.

request-sample

Cancer Diagnostics Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 41,542.4 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 9.2% 2027 Value Projection: US$ 83,641.9 Mn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: South Africa, North Africa, Central Africa
Segments covered:
  • By Test Type:
    • Tumor Biomarkers Tests: PSA Tests, CTC Tests, AFP Tests, CA-19 Tests, HER2 Tests, BRCA Tests, ALK Tests, CEA Tests, EGFR Mutation Tests, KRAS Mutation Tests, Others.
    • Imaging: Ultrasound, Mammography, MRI Scan, PET Scan, CT Scan, SPECT & Others.
    • Biopsy: Needle Biopsy, Endoscopic Biopsy, Bone Marrow Biopsy, Others.
    • Liquid Biopsy
    • Immunohistochemistry
    • In Situ Hybridization
  • By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Blood Cancers, Prostate Cancer, Ovarian Cancer, Stomach Cancer, Liver Cancer, Others.
  • By End User: Hospital Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Others.
Companies covered:

Abbott Laboratories, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Siemens AG, Bio Rad Laboratories Inc., GE Healthcare, Illumina, Inc., Koninklijke Philips N.V., Toshiba Medical Systems Corporation, Agilent Technologies, Inc., Aurora Imaging Technologies, Inc., and Quest Diagnostics

Growth Drivers:
  • High prevalence of cancer
  • Number of diagnostic options
Restraints & Challenges:
  • High costs
  • Inadequate reimbursement

Global Cancer Diagnostics Market: Opportunities 

Development of biopsy platforms for companion animal cancers is expected to offer lucrative growth opportunities for players in the global cancer diagnostics market. For instance, in January 2020, Zomedica Pharmaceuticals Corp., a veterinary diagnostic and pharmaceutical company, announced completing the development and manufacturing of its reference lab cancer liquid biopsy platform for canine cancers.

Moreover, use of AI in early detection of cancer is also expected to aid in growth of the market. For instance, Freenome, an AI genomics company based in the U.S., is focused on developing blood tests to detect the body’s early-warning signs of cancer, using AI. In October 2018, the company presented early data in R&D for using machine learning to detect colorectal cancer at its earliest stages.

The global cancer diagnostics market was valued at US$ 41,542.4 Mn in 2019 and is forecast to reach a value of US$ 83,641.9 Mn by 2027 at a CAGR of 9.2% between 2020 and 2027.

Figure 2. Global Cancer Diagnostics Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027

Cancer Diagnostics  | Coherent Market Insights

Market Trends/Key Takeaways

Major players in the market are focused on adopting partnership strategies to enhance their market share. For instance, in February 2020, Foundation Medicine, Inc. and Chugai Pharmaceutical, Ltd. collaborated with National Cancer Center (NCC) for the use of FoundationOneLiquid, Foundation Medicine’s laboratory-developed liquid biopsy test, in the third stage of SCRUM-Japan, a cancer genomic screening consortium in Japan.

Major players in the market are also focused on adopting M&A strategies to expand their product portfolio. For instance, in January 2020, Quest Diagnostics acquired Blueprint Genetics to expand its product portfolio in genetic and rare diseases.

Global Cancer Diagnostics Market: Competitive Landscape

Major players operating in the global cancer diagnostics market include, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Siemens AG, Bio Rad Laboratories Inc., GE Healthcare, Illumina, Inc., Koninklijke Philips N.V., Toshiba Medical Systems Corporation, Agilent Technologies, Inc., Aurora Imaging Technologies, Inc., Quest Diagnostics

Global Cancer Diagnostics Market: Key Developments

Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, in May 2020, Myriad Genetics, Inc. received the U.S. Food and Drug Administration (FDA) approval for its BRACAnalysis CDx test as a CDx for Lynparza in homologous recombination repair-mutated metastatic castration-resistant prostate cancer.

Major players in the market are also focused on adopting partnership strategies to expand their product portfolio. For instance, in October 2019, Illumina, Inc. partnered with QIAGEN N.V. to broaden the availability and use of NGS-based in-vitro diagnostic kits, including companion diagnostics, for patient management.

Cancer diagnostics are procedures used for the identification of cancer with or without incision in the body. Detection and treatment of cancer at early stages are important for long-term survival. Non-invasive cancer detection method is found to be an increasing choice of interest, owing to its painless or minimal pain method of diagnostic coupled with more accurate results. Molecular based diagnostic methods are expected to increase during the forecast period due to launches of new biomarker based detection methods. Moreover, factors like increasing incidence of cancer, increasing cancer screening rate, government initiatives, and emerging technologies such as next generation sequencing are expected to drive the market during the forecast period.

Restraints of the Global Cancer Diagnostics Market

Major factors hampering the growth of the cancer diagnostics market during the forecast period constitutes of high costs, and inadequate reimbursement.

Key features of the study:

  • This report provides in-depth analysis of the global cancer diagnostics market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2020–2027), considering 2019, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global cancer diagnostics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Siemens AG, Bio Rad Laboratories Inc., GE Healthcare, Illumina, Inc., Koninklijke Philips N.V., Toshiba Medical Systems Corporation, Agilent Technologies, Inc., Aurora Imaging Technologies, Inc., and Quest Diagnostics
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global cancer diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Cancer Diagnostics Market, By Test Type:
    • Tumor Biomarkers Tests
      • PSA Tests
      • CTC Tests
      • AFP Tests
      • CA-19 Tests
      • HER2 Tests
      • BRCA Tests
      • ALK Tests
      • CEA Tests
      • EGFR Mutation Tests
      • KRAS Mutation Tests
      • Others
    • Imaging
      • Ultrasound
      • Mammography
      • MRI Scan
      • PET Scan
      • CT Scan
      • SPECT & Others
    • Biopsy
      • Needle Biopsy
      • Endoscopic Biopsy
      • Bone Marrow Biopsy
      • Others
    • Liquid Biopsy
    • Immunohistochemistry
    • In Situ Hybridization
  • Global Cancer Diagnostics Market, By Cancer Type:
    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Melanoma
    • Blood Cancers
    • Prostate Cancer
    • Ovarian Cancer
    • Stomach Cancer
    • Liver Cancer
    • Others
  • Global Cancer Diagnostics Market, By End User:
    • Hospital Associated Labs
    • Independent Diagnostic Laboratories
    • Diagnostic Imaging Centers
    • Cancer Research Institutes
    • Others
  • Global Cancer Diagnostics Market, By Geography:
    • North America
      • By Test Type
        • Tumor Biomarkers Tests
          • PSA Tests
          • CTC Tests
          • AFP Tests
          • CA-19 Tests
          • HER2 Tests
          • BRCA Tests
          • ALK Tests
          • CEA Tests
          • EGFR Mutation Tests
          • KRAS Mutation Tests
          • Others
        • Imaging
          • Ultrasound
          • Mammography
          • MRI Scan
          • PET Scan
          • CT Scan
          • SPECT & Others
        • Biopsy
          • Needle Biopsy
          • Endoscopic Biopsy
          • Bone Marrow Biopsy
          • Others
        • Liquid Biopsy
        • Immunohistochemistry
        • In Situ Hybridization
      • By Cancer Type
        • Breast Cancer
        • Lung Cancer
        • Colorectal Cancer
        • Melanoma
        • Blood Cancers
        • Prostate Cancer
        • Ovarian Cancer
        • Stomach Cancer
        • Liver Cancer
        • Others
      • By End User
        • Hospital Associated Labs
        • Independent Diagnostic Laboratories
        • Diagnostic Imaging Centers
        • Cancer Research Institutes
        • Others
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Test Type
        • Tumor Biomarkers Tests
          • PSA Tests
          • CTC Tests
          • AFP Tests
          • CA-19 Tests
          • HER2 Tests
          • BRCA Tests
          • ALK Tests
          • CEA Tests
          • EGFR Mutation Tests
          • KRAS Mutation Tests
          • Others
        • Imaging
          • Ultrasound
          • Mammography
          • MRI Scan
          • PET Scan
          • CT Scan
          • SPECT & Others
        • Biopsy
          • Needle Biopsy
          • Endoscopic Biopsy
          • Bone Marrow Biopsy
          • Others
        • Liquid Biopsy
        • Immunohistochemistry
        • In Situ Hybridization
      • By Cancer Type
        • Breast Cancer
        • Lung Cancer
        • Colorectal Cancer
        • Melanoma
        • Blood Cancers
        • Prostate Cancer
        • Ovarian Cancer
        • Stomach Cancer
        • Liver Cancer
        • Others
      • By End User
        • Hospital Associated Labs
        • Independent Diagnostic Laboratories
        • Diagnostic Imaging Centers
        • Cancer Research Institutes
        • Others
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Test Type
        • Tumor Biomarkers Tests
          • PSA Tests
          • CTC Tests
          • AFP Tests
          • CA-19 Tests
          • HER2 Tests
          • BRCA Tests
          • ALK Tests
          • CEA Tests
          • EGFR Mutation Tests
          • KRAS Mutation Tests
          • Others
        • Imaging
          • Ultrasound
          • Mammography
          • MRI Scan
          • PET Scan
          • CT Scan
          • SPECT & Others
        • Biopsy
          • Needle Biopsy
          • Endoscopic Biopsy
          • Bone Marrow Biopsy
          • Others
        • Liquid Biopsy
        • Immunohistochemistry
        • In Situ Hybridization
      • By Cancer Type
        • Breast Cancer
        • Lung Cancer
        • Colorectal Cancer
        • Melanoma
        • Blood Cancers
        • Prostate Cancer
        • Ovarian Cancer
        • Stomach Cancer
        • Liver Cancer
        • Others
      • By End User
        • Hospital Associated Labs
        • Independent Diagnostic Laboratories
        • Diagnostic Imaging Centers
        • Cancer Research Institutes
        • Others
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Test Type
        • Tumor Biomarkers Tests
          • PSA Tests
          • CTC Tests
          • AFP Tests
          • CA-19 Tests
          • HER2 Tests
          • BRCA Tests
          • ALK Tests
          • CEA Tests
          • EGFR Mutation Tests
          • KRAS Mutation Tests
          • Others
        • Imaging
          • Ultrasound
          • Mammography
          • MRI Scan
          • PET Scan
          • CT Scan
          • SPECT & Others
        • Biopsy
          • Needle Biopsy
          • Endoscopic Biopsy
          • Bone Marrow Biopsy
          • Others
        • Liquid Biopsy
        • Immunohistochemistry
        • In Situ Hybridization
      • By Cancer Type
        • Breast Cancer
        • Lung Cancer
        • Colorectal Cancer
        • Melanoma
        • Blood Cancers
        • Prostate Cancer
        • Ovarian Cancer
        • Stomach Cancer
        • Liver Cancer
        • Others
      • By End User
        • Hospital Associated Labs
        • Independent Diagnostic Laboratories
        • Diagnostic Imaging Centers
        • Cancer Research Institutes
        • Others
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East:
      • By Test Type
        • Tumor Biomarkers Tests
          • PSA Tests
          • CTC Tests
          • AFP Tests
          • CA-19 Tests
          • HER2 Tests
          • BRCA Tests
          • ALK Tests
          • CEA Tests
          • EGFR Mutation Tests
          • KRAS Mutation Tests
          • Others
        • Imaging
          • Ultrasound
          • Mammography
          • MRI Scan
          • PET Scan
          • CT Scan
          • SPECT & Others
        • Biopsy
          • Needle Biopsy
          • Endoscopic Biopsy
          • Bone Marrow Biopsy
          • Others
        • Liquid Biopsy
        • Immunohistochemistry
        • In Situ Hybridization
      • By Cancer Type
        • Breast Cancer
        • Lung Cancer
        • Colorectal Cancer
        • Melanoma
        • Blood Cancers
        • Prostate Cancer
        • Ovarian Cancer
        • Stomach Cancer
        • Liver Cancer
        • Others
      • By End User
        • Hospital Associated Labs
        • Independent Diagnostic Laboratories
        • Diagnostic Imaging Centers
        • Cancer Research Institutes
        • Others
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Test Type
        • Tumor Biomarkers Tests
          • PSA Tests
          • CTC Tests
          • AFP Tests
          • CA-19 Tests
          • HER2 Tests
          • BRCA Tests
          • ALK Tests
          • CEA Tests
          • EGFR Mutation Tests
          • KRAS Mutation Tests
          • Others
        • Imaging
          • Ultrasound
          • Mammography
          • MRI Scan
          • PET Scan
          • CT Scan
          • SPECT & Others
        • Biopsy
          • Needle Biopsy
          • Endoscopic Biopsy
          • Bone Marrow Biopsy
          • Others
        • Liquid Biopsy
        • Immunohistochemistry
        • In Situ Hybridization
      • By Cancer Type
        • Breast Cancer
        • Lung Cancer
        • Colorectal Cancer
        • Melanoma
        • Blood Cancers
        • Prostate Cancer
        • Ovarian Cancer
        • Stomach Cancer
        • Liver Cancer
        • Others
      • By End User
        • Hospital Associated Labs
        • Independent Diagnostic Laboratories
        • Diagnostic Imaging Centers
        • Cancer Research Institutes
        • Others
      • By Country/Region:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Abbott Laboratories *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • F. Hoffmann-La Roche Ltd.
    • Thermo Fisher Scientific Inc.
    • Siemens AG
    • Bio Rad Laboratories Inc.
    • GE Healthcare
    • Illumina, Inc.
    • Koninklijke Philips N.V.
    • Toshiba Medical Systems Corporation
    • Agilent Technologies, Inc.
    • Aurora Imaging Technologies, Inc.
    • Quest Diagnostics

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Test Type
      • Market Snippet, By Cancer Type
      • Market Snippet, By End User
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
    • COVID-19 Impact Analysis
  4. Global Cancer Diagnostics Market, By Test Type, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Tumor Biomarkers Tests
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
        • PSA Tests
        • CTC Tests
        • AFP Tests
        • CA-19 Tests
        • HER2 Tests
        • BRCA Tests
        • ALK Tests
        • CEA Tests
        • EGFR Mutation Tests
        • KRAS Mutation Tests
        • Others
    • Imaging
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
        • Ultrasound
        • Mammography
        • MRI Scan
        • PET Scan
        • CT Scan
        • SPECT & Others
    • Biopsy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
        • Needle Biopsy
        • Endoscopic Biopsy
        • Bone Marrow Biopsy
        • Others
    • Liquid Biopsy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Immunohistochemistry
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • In Situ Hybridization
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
  5. Global Cancer Diagnostics Market, By Cancer Type, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Breast Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Lung Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Colorectal Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Melanoma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Blood Cancers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Prostate Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Ovarian Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Stomach Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Liver Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Cancer Diagnostics Market, By End User, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Hospital Associated Labs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Independent Diagnostic Laboratories
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Diagnostic Imaging Centers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Cancer Research Institutes
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global Cancer Diagnostics Market, By Regions, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  8. Competitive Landscape
    • Company Profiles
      • Abbott Laboratories
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Hoffmann-La Roche Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Thermo Fisher Scientific Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Siemens AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Bio Rad Laboratories Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • GE Healthcare
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Illumina, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Koninklijke Philips N.V.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Toshiba Medical Systems Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Agilent Technologies, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Aurora Imaging Technologies, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Quest Diagnostics
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 38 market data tables and 56 figures on “Cancer Diagnostics Market – Global forecast to 2027.

Frequently Asked Questions

The global cancer diagnostics market was valued at US$ 41,542.4 Mn in 2019 and is forecast to reach a value of US$ 83,641.9 Mn by 2027 at a CAGR of 9.2% between 2020 and 2027.
Major factor driving the growth of global cancer diagnostics market during the forecast period include high prevalence of cancer, and number of diagnostic options.
Major factors hampering the growth of the cancer diagnostics market during the forecast period constitutes of high costs, and inadequate reimbursement.
Biopsy held dominant position in the global cancer diagnostics market in 2019.
North America Cancer Diagnostics market is expected to generate the highest revenue during the forecast period.
Some of the key players operating in the market are Abbott Laboratories, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Siemens AG, Bio Rad Laboratories Inc., GE Healthcare, Illumina, Inc., Koninklijke Philips N.V., Toshiba Medical Systems Corporation, Agilent Technologies, Inc., Aurora Imaging Technologies, Inc., and Quest Diagnostics.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner